PHATHOM PHARMACEUTICALS, INC. Defined Contribution Plan, Cost
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Defined Contribution Plan, Cost of $1.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. defined contribution plan, cost for the quarter ending 2026-06-30 was $1.30M, a 0.00% change year-over-year.
- PHATHOM PHARMACEUTICALS, INC. defined contribution plan, cost for the quarter ending 2026-03-31 was $1.60M, a 11.11% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. defined contribution plan, cost for the quarter ending 2025-12-31 was $900.00K, a 0.00% change year-over-year.
- PHATHOM PHARMACEUTICALS, INC. defined contribution plan, cost for the quarter ending 2025-09-30 was $1.20M, a 0.00% change year-over-year.
- PHATHOM PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2025 was $5.20M, a 1.96% increase from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2024 was $5.10M, a 168.42% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2023 was $1.90M, a 46.15% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2022 was $1.30M, a 62.50% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.30M 10-Q · filed 2026-07-30 | $2.90M 10-Q · filed 2026-07-30 | $3.80M derived: sum of 3 quarters · filed 2026-07-30 | $5.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $1.60M 10-Q · filed 2026-04-30 | $2.50M derived: sum of 2 quarters · filed 2026-04-30 | $3.70M derived: sum of 3 quarters · filed 2026-04-30 | $5.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.10M derived: sum of 2 quarters · filed 2026-02-26 | $3.40M derived: sum of 3 quarters · filed 2026-07-30 | $5.20M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.20M 10-Q · filed 2025-10-30 | $2.50M derived: sum of 2 quarters · filed 2026-07-30 | $4.30M 10-Q · filed 2025-10-30 | $5.20M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.30M 10-Q · filed 2026-07-30 | $3.10M 10-Q · filed 2026-07-30 | $4.00M derived: sum of 3 quarters · filed 2026-07-30 | $5.20M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $1.80M 10-Q · filed 2026-04-30 | $2.70M derived: sum of 2 quarters · filed 2026-04-30 | $3.90M derived: sum of 3 quarters · filed 2026-04-30 | $5.20M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.10M derived: sum of 2 quarters · filed 2026-02-26 | $3.40M derived: sum of 3 quarters · filed 2026-02-26 | $5.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.20M 10-Q · filed 2025-10-30 | $2.50M derived: sum of 2 quarters · filed 2025-10-30 | $4.20M 10-Q · filed 2025-10-30 | $4.60M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $1.30M 10-Q · filed 2025-08-07 | $3.00M 10-Q · filed 2025-08-07 | $3.40M derived: sum of 3 quarters · filed 2025-08-07 | $3.70M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.70M 10-Q · filed 2025-05-01 | $2.10M derived: sum of 2 quarters · filed 2025-05-01 | $2.40M derived: sum of 3 quarters · filed 2025-05-01 | $2.80M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $700.00K derived: sum of 2 quarters · filed 2025-03-06 | $1.10M derived: sum of 3 quarters · filed 2025-03-06 | $1.90M 10-K · filed 2025-03-06 |
| 2023-09-30 | $300.00K 10-Q · filed 2024-11-07 | $700.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.50M 10-Q · filed 2024-11-07 | $1.70M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $400.00K 10-Q · filed 2024-08-08 | $1.20M 10-Q · filed 2024-08-08 | $1.40M derived: sum of 3 quarters · filed 2024-08-08 | $1.60M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $800.00K 10-Q/A · filed 2024-06-14 | $1.00M derived: sum of 2 quarters · filed 2024-06-14 | $1.20M derived: sum of 3 quarters · filed 2024-06-14 | $1.50M derived: sum of 4 quarters · filed 2024-06-14 |
| 2022-12-31 | $200.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $400.00K derived: sum of 2 quarters · filed 2024-06-14 | $700.00K derived: sum of 3 quarters · filed 2024-06-14 | $1.30M 10-K/A · filed 2024-06-14 |
| 2022-09-30 | $200.00K 10-Q · filed 2023-11-09 | $500.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.10M 10-Q · filed 2023-11-09 | $1.20M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $300.00K 10-Q · filed 2023-08-10 | $900.00K 10-Q · filed 2023-08-10 | $1.00M derived: sum of 3 quarters · filed 2023-08-10 | $1.10M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $600.00K 10-Q · filed 2023-05-10 | $700.00K derived: sum of 2 quarters · filed 2023-05-10 | $800.00K derived: sum of 3 quarters · filed 2023-05-10 | $1.00M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $100.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $200.00K derived: sum of 2 quarters · filed 2023-02-28 | $400.00K derived: sum of 3 quarters · filed 2023-02-28 | $800.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | $100.00K 10-Q/A · filed 2022-11-09 | $300.00K derived: sum of 2 quarters · filed 2022-11-09 | $700.00K 10-Q/A · filed 2022-11-09 | |
| 2021-06-30 | $200.00K 10-Q · filed 2022-08-02 | $600.00K 10-Q · filed 2022-08-02 | ||
| 2021-03-31 | $400.00K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $300.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |